» Articles » PMID: 38241094

Changes in Frailty and Incident Cardiovascular Disease in Three Prospective Cohorts

Overview
Journal Eur Heart J
Date 2024 Jan 19
PMID 38241094
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Previous studies found that frailty was an important risk factor for cardiovascular disease (CVD). However, previous studies only focused on baseline frailty status, not taking into consideration the changes in frailty status during follow-up. The aim of this study was to investigate the associations of changes in frailty status with incident CVD.

Methods: This study used data of three prospective cohorts: China Health and Retirement Longitudinal Study (CHARLS), English Longitudinal Study of Ageing (ELSA), and Health and Retirement Study (HRS). Frailty status was evaluated by the Rockwood frailty index and classified as robust, pre-frail, or frail. Changes in frailty status were assessed by frailty status at baseline and the second survey which was two years after the baseline. Cardiovascular disease was ascertained by self-reported physician-diagnosed heart disease (including angina, heart attack, congestive heart failure, and other heart problems) or stroke. Cox proportional hazard models were used to calculate the hazard ratio (HR) and 95% confidence interval (95% CI) after adjusting for potential confounders.

Results: A total of 7116 participants from CHARLS (female: 48.6%, mean age: 57.4 years), 5303 from ELSA (female: 57.7%, mean age: 63.7 years), and 7266 from HRS (female: 64.9%, mean age: 65.1 years) were included according to inclusion and exclusion criteria. The median follow-up periods were 5.0 years in the CHARLS, 10.7 years in the ELSA, and 9.5 years in the HRS. Compared with stable robust participants, robust participants who progressed to pre-frail or frail status had increased risks of incident CVD (CHARLS, HR = 1.84, 95% CI: 1.54-2.21; ELSA, HR = 1.53, 95% CI: 1.25-1.86; HRS, HR = 1.59, 95% CI: 1.31-1.92). In contrast, frail participants who recovered to robust or pre-frail status presented decreased risks of incident CVD (CHARLS, HR = 0.62, 95% CI: 0.47-0.81; ELSA, HR = 0.49, 95% CI: 0.34-0.69; HRS, HR = 0.70, 95% CI: 0.55-0.89) when compared with stable frail participants. These decreased risks of incident CVD were also observed in pre-frail participants who recovered to robust status (CHARLS, HR = 0.66, 95% CI: 0.52-0.83; ELSA, HR = 0.65, 95% CI: 0.49-0.85; HRS, HR = 0.71, 95% CI: 0.56-0.91) when compared with stable pre-frail participants.

Conclusions: Different changes in frailty status are associated with different risks of incident CVD. Progression of frailty status increases incident CVD risks, while recovery of frailty status decreases incident CVD risks.

Citing Articles

Abdominal obesity and frailty progression in population across different Cardiovascular-Kidney-Metabolic syndrome stages: a nationwide longitudinal study.

Zhang C, Hao C, Liang W, Hu K, Guo T, Chen Y Diabetol Metab Syndr. 2025; 17(1):75.

PMID: 40033331 PMC: 11877786. DOI: 10.1186/s13098-025-01649-0.


Unravelling the trajectory of frailty and its influencing factors in elderly patients with coronary heart disease after percutaneous coronary intervention: protocol for a cohort study in China.

Yu Y, Zhang C, Dong Y, Rao H BMJ Open. 2025; 15(3):e089528.

PMID: 40032368 PMC: 11877232. DOI: 10.1136/bmjopen-2024-089528.


Insights into the complex relationship between triglyceride glucose-waist height ratio index, mean arterial pressure, and cardiovascular disease: a nationwide prospective cohort study.

Xu J, Cai D, Jiao Y, Liao Y, Shen Y, Shen Y Cardiovasc Diabetol. 2025; 24(1):93.

PMID: 40022080 PMC: 11871683. DOI: 10.1186/s12933-025-02657-0.


Frailty, high-sensitivity C-reactive protein and cardiovascular disease: a nationwide prospective cohort study.

Zheng L, Ye J, Liao X, Li J, Wang Q, Wang F Aging Clin Exp Res. 2025; 37(1):58.

PMID: 40021565 PMC: 11870887. DOI: 10.1007/s40520-025-02928-6.


Sarcopenia and Cardiovascular Diseases in Individuals With Diabetes or Prediabetes.

Wang X, Zeng Q, Yu X, Li S J Clin Hypertens (Greenwich). 2025; 27(3):e70024.

PMID: 40021136 PMC: 11870746. DOI: 10.1111/jch.70024.